References: Antipsychotic use during pregnancy

Austin M-P, Highet Nthe Expert Working Group. Mental health care in the perinatal period: Australian clinical practice guideline. Melbourne: Centre of Perinatal Excellence; 2017. https://www.cope.org.au/health-professionals/health-professionals-3/review-of-new-perinatal-mental-health-guidelines/
Bruno C, Cesta CE, Hjellvik V, Ulrichsen SP, Bjork MH, Esen BO, et al. Antipsychotic use during pregnancy and risk of specific neurodevelopmental disorders and learning difficulties in children: a multinational cohort study. EClinicalMedicine 2024;70:102531. https://www.ncbi.nlm.nih.gov/pubmed/38685931
Chisolm MS, Payne JL. Management of psychotropic drugs during pregnancy. BMJ 2016;532:h5918. https://www.ncbi.nlm.nih.gov/pubmed/26791406
Cohen LS, Church TR, Freeman MP, Gaccione P, Caplin PS, Kobylski LA, et al. Reproductive Safety of Lurasidone and Quetiapine: Update from the National Pregnancy Registry for Psychiatric Medications. J Womens Health (Larchmt) 2023;32(4):452-62. https://www.ncbi.nlm.nih.gov/pubmed/36716275
Haskey C, Galbally M. Mood stabilizers in pregnancy and child developmental outcomes: A systematic review. Aust N Z J Psychiatry 2017;51(11):1087–97. https://www.ncbi.nlm.nih.gov/pubmed/28825316
Huybrechts KF, Hernandez-Diaz S, Patorno E, Desai RJ, Mogun H, Dejene SZ, et al. Antipsychotic use in pregnancy and the risk for congenital malformations. JAMA Psychiatry 2016;73(9):938–46. https://www.ncbi.nlm.nih.gov/pubmed/27540849
Kulkarni J, Storch A, Baraniuk A, Gilbert H, Gavrilidis E, Worsley R. Antipsychotic use in pregnancy. Expert Opin Pharmacother 2015;16(9):1335–45. https://www.ncbi.nlm.nih.gov/pubmed/26001182
McAllister-Williams RH, Baldwin DS, Cantwell R, Easter A, Gilvarry E, Glover V, et al. British Association for Psychopharmacology consensus guidance on the use of psychotropic medication preconception, in pregnancy and postpartum 2017. J Psychopharmacol 2017;31(5):519–52. https://www.ncbi.nlm.nih.gov/pubmed/28440103
Montiel C, Newmark RL, Clark CT. Perinatal use of lurasidone for the treatment of bipolar disorder. Exp Clin Psychopharmacol 2022;30(2):249-52. https://www.ncbi.nlm.nih.gov/pubmed/34291994
National Institute for Health and Care Excellence (NICE). Antenatal and postnatal mental health: clinical management and service guidance [cg192]. London: NICE; 2014 (updated 2020). https://www.nice.org.uk/guidance/cg192
Straub L, Hernandez-Diaz S, Bateman BT, Wisner KL, Gray KJ, Pennell PB, et al. Association of Antipsychotic Drug Exposure in Pregnancy With Risk of Neurodevelopmental Disorders: A National Birth Cohort Study. JAMA Intern Med 2022;182(5):522-33. https://www.ncbi.nlm.nih.gov/pubmed/35343998
Uguz F. Antipsychotic use during pregnancy and the risk of gestational diabetes mellitus: A systematic review. J Clin Psychopharmacol 2019;39(2):162–7. https://www.ncbi.nlm.nih.gov/pubmed/30624301
Vigod SN, Gomes T, Wilton AS, Taylor VH, Ray JG. Antipsychotic drug use in pregnancy: high dimensional, propensity matched, population based cohort study. BMJ 2015;350:h2298. https://www.ncbi.nlm.nih.gov/pubmed/25972273